Utility of triazole antifungal therapeutic drug monitoring: Insights from the Society of Infectious Diseases Pharmacists: Endorsed by the Mycoses Study Group Education and Research Consortium.
fluconazole
isavuconazole
itraconazole
pharmacodynamics
pharmacokinetics
posaconazole
voriconazole
Journal
Pharmacotherapy
ISSN: 1875-9114
Titre abrégé: Pharmacotherapy
Pays: United States
ID NLM: 8111305
Informations de publication
Date de publication:
10 2023
10 2023
Historique:
revised:
23
05
2023
received:
27
03
2023
accepted:
26
05
2023
medline:
13
10
2023
pubmed:
17
7
2023
entrez:
17
7
2023
Statut:
ppublish
Résumé
Triazole antifungals (i.e., fluconazole, itraconazole, voriconazole, posaconazole, and isavuconazole) are commonly used in clinical practice to prevent or treat invasive fungal infections. Most triazole antifungals require therapeutic drug monitoring (TDM) due to highly variable pharmacokinetics, known drug interactions, and established relationships between exposure and response. On behalf of the Society of Infectious Diseases Pharmacists (SIDP), this insight describes the pharmacokinetic principles and pharmacodynamic targets of commonly used triazole antifungals and provides the rationale for utility of TDM within each agent.
Substances chimiques
Antifungal Agents
0
Triazoles
0
Voriconazole
JFU09I87TR
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1043-1050Informations de copyright
© 2023 Pharmacotherapy Publications, Inc.
Références
Bongomin F, Gago S, Oladele RO, Denning DW. Global and multi-National Prevalence of fungal diseases-estimate precision. J Fungi. 2017;3(4):57. doi:10.3390/jof3040057
Rayens E, Norris KA. Prevalence and healthcare burden of fungal infections in the United States, 2018. Open Forum Infect Dis. 2022;9(1):ofab593. doi:10.1093/ofid/ofab593
Ostrosky-Zeichner L, Nguyen MH, Bubalo J, et al. Multicenter registry of patients receiving systemic Mold-active triazoles for the Management of Invasive Fungal Infections. Infect Dis Ther. 2022;11(4):1609-1629. doi:10.1007/s40121-022-00661-5
Park WB, Kim NH, Kim KH, et al. The effect of therapeutic drug monitoring on safety and efficacy of voriconazole in invasive fungal infections: a randomized controlled trial. Clin Infect Dis. 2012;55(8):1080-1087. doi:10.1093/cid/cis599
Lindsay J, Krantz EM, Morris J, et al. Voriconazole in hematopoietic stem cell transplantation and cellular therapies: real-world usage and therapeutic level attainment at a major transplantation center. Transplant Cell Ther. 2022;28(8):511. doi:10.1016/j.jtct.2022.05.030
Takesue Y, Hanai Y, Oda K, et al. Clinical practice guideline for the therapeutic drug monitoring of voriconazole in non-Asian and Asian adult patients: consensus review by the Japanese Society of Chemotherapy and the Japanese Society of Therapeutic Drug Monitoring. Clin Ther. 2022;44(12):1604-1623. doi:10.1016/j.clinthera.2022.10.005
Karthaus M, Lehrnbecher T, Lipp HP, Kluge S, Buchheidt D. Therapeutic drug monitoring in the treatment of invasive aspergillosis with voriconazole in cancer patients-an evidence-based approach. Ann Hematol. 2015;94(4):547-556. doi:10.1007/s00277-015-2333-z
Pascual A, Calandra T, Bolay S, Buclin T, Bille J, Marchetti O. Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes. Clin Infect Dis. 2008;46(2):201-211. doi:10.1086/524669
Luong ML, Al-Dabbagh M, Groll AH, et al. Utility of voriconazole therapeutic drug monitoring: a meta-analysis. J Antimicrob Chemother. 2016;71(7):1786-1799. doi:10.1093/jac/dkw099
Yang P, Liu W, Zheng J, et al. Predicting the outcome of voriconazole individualized medication using integrated pharmacokinetic/pharmacodynamic model. Front Pharmacol. 2021;12:711187. doi:10.3389/fphar.2021.711187
Mangal N, Hamadeh IS, Arwood MJ, et al. Optimization of voriconazole therapy for the treatment of invasive fungal infections in adults. Clin Pharmacol Ther. 2018;104(5):957-965. doi:10.1002/cpt.1012
Hope W, Johnstone G, Cicconi S, et al. Software for dosage individualization of voriconazole: a prospective clinical study. Antimicrob Agents Chemother. 2019;63(4):e02353. doi:10.1128/AAC.02353-18
Chau MM, Daveson K, Alffenaar JC, et al. Consensus guidelines for optimising antifungal drug delivery and monitoring to avoid toxicity and improve outcomes in patients with haematological malignancy and haemopoietic stem cell transplant recipients, 2021. Intern Med J. 2021;51(Suppl 7):37-66. doi:10.1111/imj.15587
Moriyama B, Obeng AO, Barbarino J, et al. Clinical pharmacogenetics implementation consortium (CPIC) guidelines for CYP2C19 and voriconazole therapy. Clin Pharmacol Ther. 2017;102(1):45-51. doi:10.1002/cpt.583
Whirl-Carrillo M, McDonagh EM, Hebert JM, et al. Pharmacogenomics knowledge for personalized medicine. Clin Pharmacol Ther. 2012;92(4):414-417. doi:10.1038/clpt.2012.96
Di Paolo M, Hewitt L, Nwanko E, et al. A retrospective 'real-world' cohort study of azole therapeutic drug monitoring and evolution of antifungal resistance in cystic fibrosis. JAC Antimicrob Resist. 2021;3(1):dlab026. doi:10.1093/jacamr/dlab026
Whitmore TJ, Yaw M, Lavender M, Musk M, Boan P, Wrobel J. A novel highly bio-available itraconazole formulation (SUBA(R)-itraconazole) for anti-fungal prophylaxis in lung transplant recipients. Transpl Infect Dis. 2021;23(4):e13587. doi:10.1111/tid.13587
Nield B, Larsen SR, van Hal SJ. Clinical experience with new formulation SUBA(R)-itraconazole for prophylaxis in patients undergoing stem cell transplantation or treatment for haematological malignancies. J Antimicrob Chemother. 2019;74(10):3049-3055. doi:10.1093/jac/dkz303
Dolton MJ, Ray JE, Chen SC, Ng K, Pont L, McLachlan AJ. Multicenter study of posaconazole therapeutic drug monitoring: exposure-response relationship and factors affecting concentration. Antimicrob Agents Chemother. 2012;56(11):5503-5510. doi:10.1128/AAC.00802-12
Wiederhold NP, Pennick GJ, Dorsey SA, et al. A reference laboratory experience of clinically achievable voriconazole, posaconazole, and itraconazole concentrations within the bloodstream and cerebral spinal fluid. Antimicrob Agents Chemother. 2014;58(1):424-431. doi:10.1128/AAC.01558-13
Cornely OA, Duarte RF, Haider S, et al. Phase 3 pharmacokinetics and safety study of a posaconazole tablet formulation in patients at risk for invasive fungal disease. J Antimicrob Chemother. 2016;71(3):718-726. doi:10.1093/jac/dkv380
Maertens J, Cornely OA, Ullmann AJ, et al. Phase 1B study of the pharmacokinetics and safety of posaconazole intravenous solution in patients at risk for invasive fungal disease. Antimicrob Agents Chemother. 2014;58(7):3610-3617. doi:10.1128/AAC.02686-13
Duarte RF, Lopez-Jimenez J, Cornely OA, et al. Phase 1b study of new posaconazole tablet for prevention of invasive fungal infections in high-risk patients with neutropenia. Antimicrob Agents Chemother. 2014;58(10):5758-5765. doi:10.1128/AAC.03050-14
Maertens JA, Rahav G, Lee DG, et al. Posaconazole versus voriconazole for primary treatment of invasive aspergillosis: a phase 3, randomised, controlled, non-inferiority trial. Lancet. 2021;397(10273):499-509. doi:10.1016/S0140-6736(21)00219-1
Jung DS, Tverdek FP, Kontoyiannis DP. Switching from posaconazole suspension to tablets increases serum drug levels in leukemia patients without clinically relevant hepatotoxicity. Antimicrob Agents Chemother. 2014;58(11):6993-6995. doi:10.1128/AAC.04035-14
Tverdek FP, Heo ST, Aitken SL, Granwehr B, Kontoyiannis DP. Real-life assessment of the safety and effectiveness of the new tablet and intravenous formulations of Posaconazole in the prophylaxis of invasive fungal infections via analysis of 343 courses. Antimicrob Agents Chemother. 2017;61(8):e00188. doi:10.1128/AAC.00188-17
Jansen AME, Muilwijk EW, van der Velden W, et al. Posaconazole bioavailability of the solid oral tablet is reduced during severe intestinal mucositis. Clin Microbiol Infect. 2022;28(7):1003-1009. doi:10.1016/j.cmi.2022.01.029
Pettit NN, Miceli MH, Rivera CG, et al. Multicentre study of posaconazole delayed-release tablet serum level and association with hepatotoxicity and QTc prolongation. J Antimicrob Chemother. 2017;72(8):2355-2358. doi:10.1093/jac/dkx122
Tang LA, Marini BL, Benitez L, et al. Risk factors for subtherapeutic levels of posaconazole tablet. J Antimicrob Chemother. 2017;72(10):2902-2905. doi:10.1093/jac/dkx228
Dieringer TD, Schaenman JM, Davis MR. Enteral feeding tube administration with therapeutic drug monitoring of crushed posaconazole tablets and opened isavuconazonium sulfate capsules. J Antimicrob Chemother. 2022;77(5):1417-1423. doi:10.1093/jac/dkac035
Dekkers BGJ, Bakker M, van der Elst KCM, et al. Therapeutic drug monitoring of Posaconazole: an update. Curr Fungal Infect Rep. 2016;10:51-61. doi:10.1007/s12281-016-0255-4
Cornely OA, Ullmann AJ. Lack of evidence for exposure-response relationship in the use of posaconazole as prophylaxis against invasive fungal infections. Clin Pharmacol Ther. 2011;89(3):351-352. doi:10.1038/clpt.2010.261
Nguyen MH, Davis MR, Wittenberg R, et al. Posaconazole serum drug levels associated with Pseudohyperaldosteronism. Clin Infect Dis. 2020;70(12):2593-2598. doi:10.1093/cid/ciz741
Ashbee HR, Barnes RA, Johnson EM, Richardson MD, Gorton R, Hope WW. Therapeutic drug monitoring (TDM) of antifungal agents: guidelines from the British Society for Medical Mycology. J Antimicrob Chemother. 2014;69(5):1162-1176. doi:10.1093/jac/dkt508
Muilwijk EW, de Lange DW, Schouten JA, et al. Suboptimal dosing of fluconazole in critically ill patients: time to rethink dosing. Antimicrob Agents Chemother. 2020;64(10):e00984. doi:10.1128/AAC.00984-20
Pea F, Righi E, Cojutti P, et al. Intra-abdominal penetration and pharmacodynamic exposure to fluconazole in three liver transplant patients with deep-seated candidiasis. J Antimicrob Chemother. 2014;69(9):2585-2586. doi:10.1093/jac/dku169
Kaindl T, Andes D, Engelhardt M, Saulay M, Larger P, Groll AH. Variability and exposure-response relationships of isavuconazole plasma concentrations in the phase 3 SECURE trial of patients with invasive mould diseases. J Antimicrob Chemother. 2019;74(3):761-767. doi:10.1093/jac/dky463
Andes D, Kovanda L, Desai A, Kitt T, Zhao M, Walsh TJ. Isavuconazole concentration in real-world practice: consistency with results from clinical trials. Antimicrob Agents Chemother. 2018;62(7):e00585. doi:10.1128/AAC.00585-18
McCreary EK, Nguyen MH, Davis MR, et al. Achievement of clinical isavuconazole blood concentrations in transplant recipients with isavuconazonium sulphate capsules administered via enteral feeding tube. J Antimicrob Chemother. 2020;75(10):3023-3028. doi:10.1093/jac/dkaa274
Kriegl L, Hatzl S, Zurl C, et al. Isavuconazole plasma concentrations in critically ill patients during extracorporeal membrane oxygenation. J Antimicrob Chemother. 2022;77(9):2500-2505. doi:10.1093/jac/dkac196
Hohl R, Bertram R, Kinzig M, et al. Isavuconazole therapeutic drug monitoring in critically ill ICU patients: a monocentric retrospective analysis. Mycoses. 2022;65(7):747-752. doi:10.1111/myc.13469
Gomez-Lopez A. Antifungal therapeutic drug monitoring: focus on drugs without a clear recommendation. Clin Microbiol Infect. 2020;26(11):1481-1487. doi:10.1016/j.cmi.2020.05.037
Kably B, Launay M, Derobertmasure A, Lefeuvre S, Dannaoui E, Billaud EM. Antifungal drugs TDM: trends and update. Ther Drug Monit. 2022;44(1):166-197.
Ashok A, Mangalore RP, Morrissey CO. Azole therapeutic drug monitoring and its use in the Management of invasive fungal disease. Curr Fungal Infect Rep. 2022;16(2):55-69. doi:10.1007/s12281-022-00430-4